Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page

Reactive management of pruritus induced by multikinase inhibitor treatment

General recommendation: Pruritus is commonly associated with the onset of papulopustular rash or with maculopapular rash but is most often caused by dry skin. It is important to treat the underlying cause.1

Treatment overview

Despite limited evidence for pruritus management in patients receiving targeted cancer therapy, studies in other cancer and general populations provide information applicable to treatment with EGFR inhibitors and multikinase inhibitors.1,2

Cold compresses and wet dressings may provide temporary relief of pruritus. Patients should be advised to reduce exposure to heat and sun, wear loose-fitting cotton clothes in order to reduce transpiration, keep nails finger nails short to avoid scratching (avoid cutting too short, especially toe nails) and to store moisturising products in the refrigerator.3

For mild-to-moderate pruritus, consider using a topical antipruritic agent containing menthol 0.5% (or pramoxine or doxepin), or a moderate-to-high dose corticosteroid.1, 3 Lotions containing urea or polidocanol may also soothe pruritus.4

If pruritus persists, administer non-sedating oral antihistamines (e.g. loratadine, cetirizine or fexofenadine) during the day.1, 3,4 To avoid adverse reactions, minimise the dose, especially in the elderly.1 First generation antihistamines with sedative properties such as hydroxyzine may be useful at bedtime as their sedating effect may improve sleep and reduce scratching.1, 3

For intense or widespread pruritus (grade 3), oral corticosteroids or immunosuppressive therapy are indicated.3, 6

In patients unresponsive to antihistamines, consider oral gabapentin or pregabalin, two antiepileptic agents that inhibit peripheral mediators of pruritus; however, the broad spectrum of side effects seen with these agents together with weak evidence supporting their use, makes these agents options only for second- or third-line treatment.1, 3

Patients should be evaluated weekly. With the second or third occurrence of pruritus intensifying supportive measures is advised. If symptoms worsen despite the intensified measures, drug interruption or discontinuation should be considered.

Table 31: Management of pruritus associated with multikinase inhibitors by CTCAE grade1, 3-5




  • Cold compresses and wet dressings
  • Topical therapy (menthol 0.5-3%, pramoxine 1%, doxepin)
  • Lotions containing urea or polidocanol


  • Oral antihistamine – non-sedating first (e.g. loratadine, cetirizine, fexofenadine)
  • Consider topical corticosteroid (triamcinolone acetonide 0.025%; desonide 0.05%; fluticasone proprionate 0.05%; alclometasone 0.05%)


  • Oral corticosteroid or immunosuppressive therapy
  • Oral gabapentin or pregabalin (second-line or third-line systemic therapy)


  • Not applicable


  • Doxepin
  • Menthol 0.5-3% cream
  • Pramoxine 1%
  • Urea- or polidocanol-containing lotions
  • Topical corticosteroid (triamcinolone acetonide 0.025%; desonide 0.05%; fluticasone proprionate 0.05%; alclometasone 0.05%)
  • Second-generation antihistamine (e.g. loratadine, cetirizine or fexofenadine)
  • First-generation antihistamine (e.g. hydroxyzine) 

Multikinase inhibitor treatment

Continue with/withhold the selected multikinase inhibitor treatment regimen, as recommended in the current and relevant SPC and according to the patient’s condition.

Related Links


  1. Lacouture ME, et al. MASCC Skin Toxicity Study Group. Support Care Cancer. 2011 ; 19 : 1079-95.
  2. Grande E, et al. Adv Ther. 2013; 30: 945-66.
  3. Boers-Doets CB. The TARGET SYSTEM. Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. ISBN 978-94-92070-00-5. 2014.
  4. Potthoff K, et al. Ann Oncol. 2011; 22: 524-35.
  5. National Cancer Institute Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events and Common Toxicity Criteria [v5.0]. 27 November 2017. (Accessed 15 April 2019).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.